---
title: "Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289928583.md"
description: "Acceptance of abstracts highlights Nexalin's innovative DIFS™ treatment platform, delivering 15 mA at 77.5 Hz. Clinical studies demonstrate significant enhancements in anxiety, depression, insomnia, and overall quality of life."
datetime: "2026-06-16T13:17:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289928583.md)
  - [en](https://longbridge.com/en/news/289928583.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289928583.md)
generator: "portal-rs"
---

# Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Acceptance of abstracts highlights Nexalin's innovative DIFS™ treatment platform, delivering 15 mA at 77.5 Hz. Clinical studies demonstrate significant enhancements in anxiety, depression, insomnia, and overall quality of life.

### Related Stocks

- [NXL.US](https://longbridge.com/en/quote/NXL.US.md)
- [NXLIW.US](https://longbridge.com/en/quote/NXLIW.US.md)

## Related News & Research

- [Nexalin Technology Announces $0.75M Direct Offering and $15M Equity Purchase Facility With Alumni Capital](https://longbridge.com/en/news/296538958.md)
- [Nexalin Technology prices registered direct offering of 2,419,355 shares at $0.31 each](https://longbridge.com/en/news/296538267.md)
- [Nexalin Technology Issues $1.17 Million OID Note for $1.0 Million Proceeds](https://longbridge.com/en/news/296654800.md)
- [Nexalin Technology enters USD 1.17 million unsecured note financing with institutional investor](https://longbridge.com/en/news/296654470.md)
- [EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life](https://longbridge.com/en/news/289332930.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**